Neuroendocrine tumours

Update on Cancer Therapeutics

Volumn 1, Issue 1, 2006, Pages 75-84

  Granberg, Dan ^a   Öberg, Kjell ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alpha interferon; Carcinoid; Chemoembolization; Chemotherapy; Endocrine pancreatic tumour; Liver embolization; Neuroendocrine tumours; Radiofrequency ablation; Somatostatin analogs; Targeted irradiation therapy

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETHIODIZED OIL; ETOPOSIDE; FLUOROURACIL; IODINATED POPPYSEED OIL; LANSOPRAZOLE; MITOMYCIN C; OCTREOTIDE; OMEPRAZOLE; PACLITAXEL; PANTOPRAZOLE; PEGINTERFERON ALPHA2B; POLYVINYL ALCOHOL; PROTON PUMP INHIBITOR; SOMATOSTATIN; SPONGOSTAN; STREPTOZOCIN; TOPOTECAN; VINCRISTINE;

ACROMEGALY; CANCER RADIOTHERAPY; CARCINOID; CARCINOID SYNDROME; CONTROLLED DRUG RELEASE; CUSHING SYNDROME; GASTRECTOMY; GASTRINOMA; GASTROINTESTINAL HEMORRHAGE; GLUCAGONOMA; HEART VALVE REPLACEMENT; HUMAN; INSULINOMA; LIVER TRANSPLANTATION; LUNG CARCINOID; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SOMATOSTATINOMA; STOMACH CARCINOID; THYMUS CARCINOID; TUMOR RECURRENCE; VIPOMA;

EID: 33746297418     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2006.04.007     Document Type: Review

References (100)

1. Williams E.D., and Sandler M. The classification of carcinoid tumors. Lancet 1 (1963) 238
2. Rindi G., Capella C., and Solcia E. Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors. J Mol Med 76 (1998) 413
3. Godwin II J.D. Carcinoid tumors. An analysis of 2837 cases. Cancer 36 (1975) 560
4. Modlin I.M., and Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 79 (1997) 813
5. Modlin I.M., Lye K.D., and Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97 (2003) 934
6. Arrigoni M.G., Woolner L.B., and Bernatz P.E. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg 64 (1972) 413
7. Granberg D., Eriksson B., Wilander E., et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 12 (2001) 1383
8. Wirth L.J., Carter M.R., Jänne P.A., and Johnson B.E. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer 44 (2004) 213
9. Chughtai T.S., Morin J.E., Sheiner N.M., Wilson J.A., and Mulder D.S. Bronchial carcinoid-Twenty years' experience defines a selective surgical approach. Surgery 122 (1997) 801
10. Dusmet M.E., and McKneally M.F. Pulmonary and thymic carcinoid tumors. World J Surg 20 (1996) 189
11. Schrevens L., Vansteenkiste J., Deneffe G., et al. Clinical-radiological presentation and outcome of surgically treated pulmonary carcinoid tumours: a long-term single institution experience. Lung Cancer 43 (2004) 39
12. Wick M.R., and Rosai J. Neuroendocrine neoplasms of the thymus. Pathol Res Pract 183 (1988) 188
13. Fjällskog M.-L., Granberg D.P., Welin S.L., et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92 (2001) 1101
14. Gal A.A., Kornstein M.J., Cohen C., Duarte I.G., Miller J.I., and Mansour K.A. Neuroendocrine tumors of the thymus: a clinicopathological and prognostic study. Ann Thorac Surg 72 (2001) 1179
15. Rindi G., Capella C., and Solcia E. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Q J Nucl Med 44 (2000) 13
16. Carney J.A., Go V.L.W., Fairbanks V.F., Moore S.B., Alport E.C., and Nora F.E. The syndrome of gastric argyrophil carcinoid tumors and nonantral gastric atrophy. Ann Int Med 99 (1983) 761
17. Solcia E., Capella C., Sessa F., et al. Gastric carcinoids and related endocrine growths. Digestion 35 Suppl. 1 (1986) 3
18. Solcia E., Bordi C., Creutzfeldt W., et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 41 (1988) 185
19. Solcia E., Capella C., Fiocca R., Cornaggia M., and Bosi F. The gastroenteropancreatic endocrine system and related tumors. Gastroenterol Clin North Am 18 (1989) 671
20. Cadiot G., Cattan D., and Mignon M. Diagnosis and treatment of ECL cell tumors. Yale J Biol Med 71 (1998) 311
21. Harvey R.F. Spontaneous resolution of multifocal gastric enterochromaffin-like cell carcinoid tumours. Lancet 1 (1988) 821
22. Ichikawa J., Tanabe S., Koizumi W., et al. Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy 35 (2003) 203
23. Gilligan C.J., Lawton G.P., Tang L.H., West A.B., and Modlin I.M. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 90 (1995) 338
24. Granberg D., Wilander E., Stridsberg M., Granerus G., Skogseid B., and Öberg K. Clinical symptoms, hormone profiles, treatment and prognosis in patients with gastric carcinoids. Gut 43 (1998) 223
25. Kouraklis G., Misiakos E., Glinavou A., Raftopoulos J., and Karatzas G. Management of enterochromaffin-like gastric carcinoid tumour metastasized to the liver. Scand J Gastroenterol 37 (2002) 246
26. Tomassetti P., Migliori M., Caletti G.C., Fusaroli P., Corinaldesi R., and Gullo L. Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med 343 (2000) 551
27. Richards M.L., Gauger P., Thompson N.W., and Giordano T.J. Regression of type II gastric carcinoids in multiple endocrine neoplasia type 1 patients with Zollinger-Ellison syndrome after surgical excision of all gastrinomas. World J Surg 28 (2004) 652
28. Rindi G., Luinetti O., Cornaggia M., Capella C., and Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 104 (1993) 994
29. Schindl M., Kaserer K., and Niederle B. Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment. Arch Surg 136 (2001) 49
30. Caplin M.E., Hodgson H., Dhillon A., et al. Multimodality treatment for gastric carcinoid tumor with liver metastases. Am J Gastroenterol 93 (1998) 1945
31. Örlefors H., Sundin A., Garske U., et al. Whole-body 11C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors-comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab (2005) 90
32. Hellman P., Lundström T., Öhrvall U., et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 26 (2002) 991
33. Elias D., Lasser P., Ducreux M., et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery 133 (2003) 375
34. Öberg K. Endocrine tumors of the gastrointestinal tract: systemic treatment. Anti-Cancer Drugs 5 (1994) 503
35. Frank M., Klose K.J., Wied M., Ishaque N., Schade-Brittinger C., and Arnold R. Combination therapy with octreotide and α-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 94 (1999) 1381
36. Kölby L., Persson G., Franzén S., and Ahrén B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 90 (2003) 687
37. Öberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 62 Suppl. 1 (2000) 92
38. Zhou Y., Wang S., Gobl A., and Öberg K. Interferon alpha induction of Stat1 and Stat2 and their prognostic significance in carcinoid tumors. Oncology 60 (2001) 330
39. Stuart K., Levy D.E., Anderson T., et al. Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs 22 (2004) 75
40. Ducreux M., Ruszniewski P., Chayvialle J.-A., et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95 (2000) 3276
41. Garland J., Buscombe J.R., Bouvier C., et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 17 (2003) 437
42. Ruszniewski P., Ish-Shalom S., Wymenga M., et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 80 (2004) 244
43. Raderer M., Kurtaran A., Scheithauer W., Fiebiger W., Weinlaender G., and Oberhuber G. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid. Oncology 60 (2001) 141
44. Öberg K., Norheim I., Lundqvist G., and Wide L. Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin-alone or in combination with 5-FU. Acta Oncol 26 (1987) 429
45. Tiensuu Janson E., Rönnblom L., Ahlström H., et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 3 (1992) 635
46. Ansell S.M., Pitot H.C., Burch P.A., Kvols L.K., Mahoney M.R., and Rubin J. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91 (2001) 1543
47. Kulke M.H., Kim H., Stuart K., et al. A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest 22 (2004) 353
48. Kulke M.H., Kim H., Clark J.W., et al. A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 101 (2004) 934
49. Ansell S.M., Mahoney M.R., Green E.M., and Rubin J. Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity. Am J Clin Oncol 27 (2004) 232
50. Eriksson B.K., Larsson E.G., Skogseid B.M., Löfberg A.-M., Lörelius L.-E., and Öberg K.E. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83 (1998) 2293
51. Schell S.R., Camp E.R., Caridi J.G., and Hawkins Jr. I.F. Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg 6 (2002) 664
52. Roche A., Girish B.V., de Baere T., et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 13 (2003) 136
53. Ruszniewski P., and Malka D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion 62 Suppl. 1 (2000) 79
54. Yao K.A., Talamonti M.S., Nemcek A., et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 130 (2001) 677
55. Dominguez S., Denys A., Madeira I., et al. Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol 12 (2000) 151
56. Kress O., Wagner H.J., Wied M., Klose K.J., Arnold R., and Alfke H. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors-a retrospective single-center analysis. Digestion 68 (2003) 94
57. Hellman P., Ladjevardi S., Skogseid B., Åkerström G., and Elvin A. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 26 (2002) 1052
58. Henn A.R., Levine E.A., McNulty W., and Zagoria R.J. Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. AJR Am J Roentgenol 181 (2003) 1005
59. Connolly H.M. Carcinoid heart disease: medical and surgical considerations. Cancer Control 8 (2001) 454
60. Tiensuu Janson E., Holmberg L., Stridsberg M., et al. Carcinoid Tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8 (1997) 685
61. Heah S.-M., Eu K.W., Ooi B.S., Ho Y.H., and Seow-Choen F. Tumor size is irrelevant in predicting malignant potential of carcinoid tumors of the rectum. Tech Coloproctol 5 (2001) 73
62. Hirschowitz B.I. Zollinger-Ellison syndrome: pathogenesis, diagnosis, and management. Am J Gastroenterol 92 4 Suppl. (1997) 44S
63. Moertel C.G., Hanley J.A., and Johnson L.A. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303 (1980) 1189
64. Moertel C.G., Lefkopoulo M., Lipsitz S., Hahn R.G., and Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (1992) 519
65. McCollum A.D., Kulke M.H., Ryan D.P., et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 27 (2004) 485
66. Delaunoit T., Ducreux M., Boige V., et al. The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?. Eur J Cancer 40 (2004) 515
67. Kouvaraki M.A., Ajani J.A., Hoff P., et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22 (2004) 4762
68. Moertel C.G., Kvols L.K., ÓConnell M.J., and Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68 (1991) 227
69. Mitry E., Baudin E., Ducreux M., et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81 (1999) 1351
70. Bajetta E., Rimassa L., Carnaghi C., et al. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 83 (1998) 372
71. Bajetta E., Ferrari L., Procopio G., et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 13 (2002) 614
72. Eriksson, B, Öberg, K. An update of the medical treatment of malignant endocrine pancreatic tumors 1993;32:203.
73. Fjällskog M.-L., Sundin A., Westlin J.-E., Öberg K., Janson E.T., and Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of α-interferon and somatostatin analogs. Med Oncol 19 (2002) 35
74. Sato T., Konishi K., Kimura H., et al. Strategy for pancreatic endocrine tumors. Hepatogastroenterology 47 (2000) 537
75. Scott A., Hinwood D., and Donnelly R. Radio-frequency ablation for symptom control in a patient with metastatic pancreatic insulinoma. Clin Endocrinol (Oxf.) 56 (2002) 557
76. Ahlman H., Friman S., Cahlin C., et al. Liver transplantation for treatment of metastatic neuroendocrine tumors. Ann NY Acad Sci 1014 (2004) 265
77. Florman S., Toure B., Kim L., et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 8 (2004) 208
78. Lew E.A., Pisegna J.R., Starr J.A., et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 118 (2000) 696
79. Eriksson B., Skogseid B., Lundqvist G., Wide L., Wilander E., and Öberg K. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 65 (1990) 1883
80. Grieco A., Bianco A., Alfei B., et al. Liver metastases of endocrine tumour associated with multiple endocrine neoplasia type 1: a sustained response to interferon therapy or a peculiar benign course?. Hepatogastroenterology 47 (2000) 1269
81. Moscetti L., Saltarelli R., Giuliani R., Fornarini G., Bezzi M., and Cortesi E. Intra-arterial liver chemotherapy and hormone therapy in malignant insulinoma: case report and review of the literature. Tumori 86 (2000) 475
82. Arnold R., Simon B., and Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 62 Suppl. 1 (2000) 84
83. Tomassetti P., Migliori M., Corinaldesi R., and Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 14 (2000) 557
84. Cellier C., Yaghi C., Cuillerier E., et al. Metastatic jejunal VIPoma: beneficial effect of combination therapy with interferon-alpha and 5-fluorouracil. Am J Gastroenterol 95 (2000) 289
85. Angeletti S., Corleto V.D., Schillaci O., et al. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 42 (1998) 792
86. Ulfberg J., Tot T., and Wilander E. Thirty-year survival with an untreated malignant duodenal somatostatinoma. Endocrine Pathol 9 (1998) 375
87. Pathirana A.A., Vinjamuri S., Byrne C., Ghaneh P., Vora J., and Poston G. (131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. Eur J Surg Oncol 27 (2001) 404
88. Safford S.D., Coleman R.E., Gockerman J.P., et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 101 (2004) 1987
89. Slooter G.D., Mearadji A., Breeman W.A., et al. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours. Br J Surg 88 (2001) 31
90. Buscombe J.R., Caplin M.E., and Hilson A.J. Long-term efficacy of high-activity 111 in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 44 (2003) 1
91. Waldherr C., Pless M., Maecke H.R., et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43 (2002) 610
92. Kwekkeboom D.J., Bakker W.H., Kam B.L., et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 30 (2003) 417
93. Breeman W.A., de Jong M., Kwekkeboom D.J., et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 28 (2001) 1421
94. Shah M.H., Young D., Kindler H.L., et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 10 (2004) 6111
95. Öberg K. Carcinoid tumors: current concepts in diagnosis and treatment. The Oncologist 3 (1998) 339
96. Öberg K. State of the art and future prospects in the management of neuroendocrine tumors. Q J Nucl Med 44 (2000) 3
97. Di Bartolomeo M., Bajetta E., Buzzoni R., et al. Clinical efficiacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer 77 (1996) 402
98. Eriksson B., Renstrup J., Imam H., and Öberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 8 (1997) 1041
99. Ruszniewski P., Ducreux M., Chayvialle J.A., et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 39 (1996) 279
100. Wymenga A.N., Eriksson B., Salmela P.I., et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 17 (1999) 1111